Welcome to our dedicated page for Agios Pharmaceuticals SEC filings (Ticker: AGIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Agios Pharmaceuticals, Inc. filings document the regulatory record of a Delaware, Nasdaq-listed commercial-stage biopharmaceutical company focused on rare diseases and hematology. Its 8-K reports furnish operating results, product revenue updates for PYRUKYND® and AQVESME™, business highlights, investor presentations, and Regulation FD disclosures tied to mitapivat commercialization, clinical programs, and regulatory interactions.
Proxy and current-report filings cover annual-meeting proposals, director elections, board-class structure, committee assignments, stockholder voting matters, and compensatory arrangements for directors. Other disclosures address board appointments, pharmacovigilance communications involving PYRUKYND, exhibit filings, and Inline XBRL cover-page data.
AGIOS PHARMACEUTICALS, INC. director David Scadden increased his equity-based holdings through option and RSU activity. On June 18, 2026, he acquired 2,816 shares of common stock via the exercise of previously granted restricted stock units, bringing his direct common stock ownership to 20,419 shares.
He also received new equity awards: 14,950 stock options with a $34.16 exercise price, vesting in full on June 18, 2027, and 2,927 new restricted stock units that also vest in full on June 18, 2027. Earlier RSUs granted on June 18, 2025 will vest in full on June 18, 2026, with shares delivered within three business days after vesting.
AGIOS PHARMACEUTICALS director Cynthia Smith reported equity compensation activity and an option exercise. On June 18, 2026, she exercised restricted stock units covering 2,816 shares of common stock, bringing her direct common stock holdings to 15,230 shares after the transaction.
She also received 14,950 stock options with an exercise price of $34.16 per share that vest in full on June 18, 2027, and 2,927 new restricted stock units that also vest on June 18, 2027. Earlier restricted stock units granted on June 18, 2025 vested in full on June 18, 2026, and the vested shares will be delivered within three business days after vesting.
AGIOS PHARMACEUTICALS, INC. reported that Chief Strategy and Operations officer Krishnan Viswanadhan acquired equity-based compensation on June 18, 2026. He received 3,000 restricted stock units, each representing a contingent right to one share of common stock, and a further 3,000 performance share units tied to clinical and research milestones. The performance share units were originally granted on March 5, 2025, and the compensation & people committee determined that the performance criteria for a specified research milestone were met as of June 18, 2026. Shares related to that milestone are scheduled to vest on December 31, 2027, subject to his continued service.
AGIOS PHARMACEUTICALS, INC. Chief Executive Officer Brian Goff reported equity compensation activity involving 39,000 shares. He received a grant of 39,000 restricted stock units, each representing a contingent right to receive one share of common stock. In addition, 39,000 performance share units tied to clinical and research milestones were exercised into underlying common stock. The performance criteria for a specified research milestone were determined to be met as of June 18, 2026, and the related shares are scheduled to vest on December 31, 2027, subject to his continued service.
AGIOS PHARMACEUTICALS, INC. Chief Legal Officer James William Burns reported routine equity compensation changes. He received a grant of 3,000 restricted stock units, each representing a right to one share of common stock. He also exercised 3,000 performance share units into common stock at no exercise price.
The performance share units were originally granted on March 1, 2025 and vest based on three specified clinical and research milestones. The compensation & people committee determined one research milestone was met as of June 18, 2026, and the related shares are scheduled to vest on December 31, 2027, subject to his continued service.
AGIOS PHARMACEUTICALS Chief Medical Officer Sarah Gheuens reported equity compensation activity involving restricted and performance share units. On June 18, 2026, she received a grant of 3,000 restricted stock units, each representing a contingent right to one share of common stock. The same day, she also acquired 3,000 shares of common stock through the exercise or conversion of 3,000 performance share units, with each unit likewise tied to one common share. These performance share units were originally granted on March 1, 2025 and vest based on three specified clinical and research milestones set by the board and its compensation and people committee. The performance criteria for one research milestone was determined to be met as of June 18, 2026, and the related shares are scheduled to vest on December 31, 2027, subject to Dr. Gheuens’s continued service. Following these transactions, she holds 3,000 restricted stock units and 9,000 performance share units, and the filing shows only acquisitions with no sales or tax-withholding dispositions.
Jones Cecilia reported acquisition or exercise transactions in this Form 4 filing.
AGIOS PHARMACEUTICALS, INC. Chief Financial Officer Cecilia Jones reported equity compensation activity involving restricted stock units and performance share units. She received a grant of 3,000 restricted stock units, each representing a contingent right to one share of common stock. A separate award of 3,000 performance share units tied to a specified research milestone had its performance criteria determined to be met as of June 18, 2026. The underlying shares for this milestone are scheduled to vest on December 31, 2027, subject to her continued service.
AGIOS PHARMACEUTICALS, INC. Chief Commercial Officer Tsveta Milanova reported equity-based compensation changes involving restricted and performance share units tied to common stock. She received 3,000 restricted stock units, each representing a contingent right to one share of common stock, bringing her holdings in that award type to 3,000 units.
She also acquired 3,000 shares through the exercise of performance share units, increasing her total directly held common stock from these derivative transactions to 9,000 shares. The performance stock units were originally granted on March 1, 2025 and vest based on three specified clinical and research milestones. The performance criteria for a specified research milestone were determined to be met as of June 18, 2026, and the related shares are scheduled to vest on December 31, 2027, subject to her continued service.
AGIOS PHARMACEUTICALS, INC. director Jay T. Backstrom received new equity awards as part of his compensation. He was granted stock options for 14,950 shares of common stock at an exercise price of $34.16 per share, vesting in full on June 18, 2027 and expiring on June 18, 2036.
He also received 2,927 restricted stock units, each representing a contingent right to one share of common stock. These RSUs vest in full on June 18, 2027, with shares to be delivered within three business days after vesting. These are routine awards, not open-market purchases or sales.
Agios Pharmaceuticals, Inc. reported that stockholders approved an amendment to its 2023 Stock Incentive Plan at the 2026 annual meeting. The amendment increases the number of shares of common stock available for issuance under the plan by 2,000,000 shares and raises the limit for incentive stock options by the same amount.
Stockholders also elected directors, including Rahul Ballal, Ph.D., Brian Goff and Cynthia Smith, and approved additional proposals, with support levels reflected in detailed vote tallies such as 48,511,213 votes for one item versus 116,938 against and 15,376 abstaining.